Medical Crossfire®: Navigating the PCSK9 Inhibitor Frontier: A Guide to Understanding the Clinical Implications of Recent PCSK9 Inhibitor Trials


Release Date: December 28, 2018
Expiration Date: December 28, 2019
Media: Internet - based

Activity Overview

This crossfire is designed to educate clinicians regarding the latest clinical trial evidence for PCSK9i, emphasizing results from studies that evaluated coronary risk and cardiovascular outcomes.

They will discuss the efficacy and safety data supporting these therapies, and the role of new therapies alongside traditional dyslipidemia treatment options.  The activity will go beyond a simple overview of the trial results to guide clinicians in how to interpret the clinical implications of the findings to improve the management of CV risk in their patients.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen Inc.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward lipidologists, cardiologists, Nurse Practitioners, Nurses, Physician Assistants, researchers, and other healthcare professionals interested in the treatment of hypercholesterolemia.

Learning Objectives

Upon completion of this activity, you should be better prepared to:

  • Determine optimal LDL-C target goals in high-risk individuals in light of current consensus recommendations.
  • Review the latest clinical trial data for the novel LDL-C lowering agents, PCSK9 inhibitors, and their potential application to address ASCVD risk in clinical practice.
  • Discuss new data and how it will benefit individualized treatment plans to improve outcomes and lower the risk of cardiovascular events for patients with dyslipidemia.

Faculty Presenters

Elliot A. Brinton, MD, FAHA, FNLA
President, Utah Lipid Center
Salt Lake City, Utah
Michael Davidson, MD, FACC, FNLA 
Professor at the University of Chicago Pritzker School of Medicine
Chicago, Illinois
Peter Salgo, MD
Professor of Medicine and Anesthesiology, Columbia University College of Physicians and Surgeons
New York, New York
James Underberg, MD 
President of the National Lipid Association, and Clinal Assistant Professor of Medicine at the New York University School of Medicine
New York, New York

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Accreditation Statement(s):

This activity is jointly provided by Global Education Group and Physicians’ Education Resource®, LLC. AMA PRA Category 1 Credit is provided by Global Education Group.

Credit Designation Statement(s):

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Physicians’ Education Resource®, LLC (PER®). Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

*Other health professionals can submit their certificate to their accreditation board to apply for credit.

Disclosure of Unlabeled Use:

This activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Instructions: To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

Faculty Disclosures:

Elliot A. Brinton, MD, FAHA, FNLA – In the past 12 months, Dr. Brinton has worked as a consultant and been in a speakers bureau for Amgen, Kowa, Regeneron, and Sanofi.
Michael Davidson, MD, FACC, FNLA  – In the past 12 months, Dr. Davidson has worked as a consultant for Sanofi US, Regeneron, Amgen, AstraZeneca, Merck, and Novo Nordisk. Dr. Davidson has also been in a speakers bureau for Novo Nordisk, Sanofi US, Amgen, and Regeneron.
Peter Salgo, MD – No financial information to disclose.
James Underberg, MD  – In the past 12 months, Dr. Underberg has  provided grant research support for Aegerion and Pfizer, worked as a consultant for Amarin and Amgen, and been in a speakers bureau for Amgen, Sanofi, Regeneron, True Health Diagnostics, Amarin, Alexioin and Kowa.

Accreditor Disclosure:

The following contributors have no relevant financial relationships with commercial interests to disclose.

Global Education Group
Planning StaffLindsay Borvansky; Andrea Funk; and Liddy Knight

Physicians' Education Resource®, LLC (PER®)
The following contributors have no relevant financial relationships with commercial interests to disclose.

Planning StaffDavid HeckardMaryjo Dixon, RPh; Neelam Davis, PharmD; and Kathleen Bowen

Educational Disclaimer

Continuing education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

System Requirements

PC-based participants
Required: Windows 7, Vista, XP, 2003 Server or 2000
Macintosh-based participants
Required: Mac OS X 10.4.11 (Tiger) or newer
For questions about this Internet CPE activity, please contact:
Privacy Policy and Terms of Use information:  

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields

Become a Member

Forgot Password?
Calendar of Events
Filter By